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Dioxin-like compounds [e.g., non-ortho- 
substituted polychlorinated biphenyls (PCBs), 
chlorinated dibenzo-p-dioxins, and chlori-
nated dibenzofurans] rank among the highest-
priority environmental toxicants at Superfund 
sites (Agency for Toxic Substances and 
Disease Registry 2007). Because these com-
pounds occur most commonly as complex 
mixtures, methods to predict the expected 
outcome of combination exposures are criti-
cal both to risk assessment and to an accurate 
judgment of whether mixture effects are addi-
tive, synergistic, or antagonistic.
A rigorous approach is to first define a 
model, sometimes called the null model, for 
the expected additive (i.e., non  interactive) 
effects of a combination. Mixture effects 
above or below those predicted can then be 
thought of as synergy or antagonism with 
respect to the null model (Kortenkamp 2007; 
U.S. Environmental Protection Agency 2000). 
Choice of the null model is crucial. An inap-
propriate null model for a mixture can greatly 
under  estimate the additive (non  interactive) 
effects of mixtures, as was demons  trated dra-
matically in an experiment measuring activa-
tion of the estrogen receptor by a mixture of 
environmental estrogenic agents (Silva et al. 
2002). Although the concentration of each 
individual agent was below its no observed 
effect concentration or effective concentration 
causing 1% of maximal response, the total 
effect of the mixture was many times greater 
than that predicted by a simple sum of the 
individual effects, a null model sometimes 
called effect summation. It is easy to show 
that the effect summation model is appropri-
ate only for agents with linear dose–response 
curves (Berenbaum 1989).
Combination effects of estrogenic agents 
in the Silva experiment (Silva et al. 2002) 
were, however, accurately predicted by the null 
model of concentration addition (CA). CA 
assumes that one agent can be substituted for 
another in proportion to their relative poten-
cies; it is usually thought to apply to agents that 
work by similar mechanisms and is not limited 
to linear dose–response curves (Kortenkamp 
2007). CA has the added advantage of a clear 
graphical interpretation: Curves of constant 
joint effect (isoboles) must be negatively sloped 
straight lines when the concentration of one 
agent is plotted against the concentration of 
the other (Berenbaum 1989).
CA has an important limitation in that 
it cannot be applied to effect levels greater 
than the maximal effect achieved by the 
least efficacious compound included in the 
mixture (Silva et al. 2002). Therefore, this 
model   cannot appropriately assess the effect 
of mixtures containing a partial agonist (i.e., 
an agonist with less than maximal efficacy). 
We previously derived a generalization of CA 
(GCA) to describe the combination effects of 
full agonists, partial agonists, and competi-
tive antagonists (Howard and Webster 2009). 
GCA provides a definition of non  interaction 
that encompasses combinations with linear iso-
boles of any slope; for example, in the case of 
the Hill function dose–response curves consid-
ered here, GCA produces a distinctive pattern 
of linear isoboles whose slopes depend on the 
type of interaction being modeled (Table 1). 
Kinetic models of combinations of full and 
partial agonists acting on simple but plausible 
receptor systems gave results identical to the 
GCA model, supporting the GCA definition 
of additivity (Howard and Webster 2009).
The toxicity of dioxin-like agents is medi-
ated by their interaction with the aryl hydro-
carbon receptor (AhR) (Fernandez-Salguero 
et al. 1996). Exogenous ligands induce AhR 
trans  location to the nucleus, dimerization with 
the AhR nuclear translocator protein, binding 
to target genes at specific DNA binding sites 
(AhREs), and activation of gene transcription 
(Denison et al. 2002). Effects of mixtures of 
dioxin-like compounds are estimated using 
the toxic equivalency factor (TEF) approach, a 
special case of CA (Van den Berg et al. 2006). 
The TEF method assumes that all individual 
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Ba c k g r o u n d: Predicting the expected outcome of a combination exposure is critical to risk 
  assessment. The toxic equivalency factor (TEF) approach used for analyzing joint effects of dioxin-
like chemicals is a special case of the method of concentration addition. However, the TEF method 
assumes that individual agents are full aryl hydrocarbon receptor (AhR) agonists with parallel dose–
response curves, whereas many mixtures include partial agonists.
oBjectives: We assessed the ability of generalized concentration addition (GCA) to predict effects 
of combinations of full AhR agonists with partial agonists or competitive antagonists.
Me t h o d s : We measured activation of AhR-dependent gene expression in H1G1.1c3 cells after appli-
cation of binary combinations of AhR ligands. A full agonist (2,3,7,8-tetrachlorodibenzo-p-  dioxin 
or 2,3,7,8-tetrachlorodibenzofuran) was combined with either a full agonist (3,3´,4,4´,5-penta-
chloro  biphenyl), a partial agonist (2,3,3´,4,4´-pentachlorobiphenyl or galangin), or an antagonist 
(3,3´-diindolylmethane). Combination effects were modeled by the TEF and GCA approaches, and 
goodness of fit of the modeled response surface to the experimental data was assessed using a non-
parametric statistical test.
re s u l t s: The GCA and TEF models fit the experimental data equally well for a mixture of two full 
agonists. In all other cases, GCA fit the experimental data significantly better than the TEF model.
co n c l u s i o n s: The TEF model overpredicts effects of AhR ligands at the highest concentration 
combinations. At lower concentrations, the difference between GCA and TEF approaches depends 
on the efficacy of the partial agonist. GCA represents a more accurate definition of additivity for 
mixtures that include partial agonist or competitive antagonist ligands.
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agents are full agonists with parallel dose–
response curves, differing only in potency. 
However, many AhR ligands, including many 
PCBs (Hestermann et al. 2000; Peters et al. 
2006), are partial agonists.
Here, we have applied the GCA model 
to mixtures of AhR ligands, including full 
agonists, partial agonists, and antagonists. 
We tested the model using experimental data 
from binary combinations of agents, gener-
ated using a cell line stably transfected with an 
AhR-driven reporter construct, and comparing 
the results with those from the TEF model. 
Finally, we describe the utility of the GCA 
model and contrast its predictions with those 
of the TEF approach.
Materials and Methods
2,3,3´,4,4´-Pentachlorobiphenyl (PCB105); 
3,3´,4,4´,5-pentachloro  biphenyl (PCB126); 
and 2,3,7,8-tetra  chloro  dibenzofuran (TCDF) 
were purchased from Cambridge Isotope 
Laboratories (Andover, MA). 2,3,7,8-Tetra-
chlorodibenzo-p-dioxin (TCDD) was 
purchased from Ultra Scientific (North 
Kingstown, RI). 3,3´-Diindolylmethane 
(DIM) and galangin were purchased from 
Sigma-Aldrich (St. Louis, MO).
Purity of the PCB105 sample was assessed 
by gas chromatography/mass spectroscopy 
using a Hewlett-Packard P5989 (Hewlett-
Packard, Palo Alto, CA). This analysis revealed 
contamination with 1.2% non-ortho PCB126 
and 1% mono-ortho PCB118 (2,3´,4,4´,5-
penta  chloro  biphenyl).
Measurement of AhR activation (H1G1 
assay). The H1G1.1c3 recombinant murine 
hepatoma cell line, kindly provided by 
M. Denison (University of California, Davis, 
Davis, California), is stably transfected 
with an EGFP (enhanced green fluorescent 
protein) reporter construct regulated by 
AhREs from the murine CYP1A1 promoter. 
H1G1.1c3 cells were cultured and prepared 
for experiments as described previously (Nagy 
et al. 2002). Briefly, H1G1.1c3 cells were 
plated at 2 × 104 cells per well in 200 µL 
medium (αMEM, 10% fetal bovine serum, 
50 U/mL penicillin/streptomycin) contain-
ing G418 (968 mg/L) and incubated at 37°C 
for 24 hr. The medium was removed and 
replaced with 100 µL non  selective medium 
before application of the test compounds. 
Stock solutions of test compounds were 
prepared and diluted in DMSO. Each experi-
ment used an array of seven plates, and each 
plate was treated with combinations of com-
pounds. The plates were treated with vehicle 
(DMSO, 0.5%), a partial agonist (PCB105 
or galangin), an antagonist (DIM), or a full 
agonist (PCB126). This was followed immedi-
ately by treatment with either vehicle (DMSO, 
0.5%) or a TCDD or a TCDF standard curve. 
After plates were incubated at 33°C for 24 hr, 
EGFP fluorescence was read with a fluorometric 
plate reader (Synergy 2, BioTek Instruments, 
Winooski, VT). The excitation and emission 
wavelengths were 485 nm (20 nm bandwidth) 
and 530 nm (25 nm bandwidth). For each 
plate, we subtracted the fluorescence measured   
in wells of untreated cells from fluorescence 
in experi  mental wells. Because gain settings 
on the plate reader varied, we report only rela-
tive fluorescence values. The eight replicates of 
each combination within a plate were averaged 
in each experiment, and each experiment was 
repeated at least three times. Detailed informa-
tion on the assay and concentrations used in 
the factorial experi  mental design are provided 
in the Supplemental Material (doi:10.1289/
ehp.0901312). 
We analyzed toxicity after the fluorescence 
meas  urement by assessing thiazolyl blue tetra-
zolium bromide labeling. Only combinations 
that had no significant toxicity (i.e., labeling 
≥ 85% of that in vehicle-treated wells) were 
used in the model analyses (data not shown). 
See Supplemental Material (doi:10.1289/
ehp.0901312) for additional details. 
Mathematical models. The GCA equa-
tion for a combination of two agonists A and 
B, with individual concentration–response 
curves fA([A]) and fB([B]), is
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where fA
–1(.) and fB
–1(.) are the inverse func-
tions of the individual concentration–response 
curves, and E is the effect level (Howard and 
Webster 2009).
We assumed that all concentration– 
response curves were Hill functions with 
Hill parameter 1: fA([A]) = αA[A]/(KA + [A]), 
where KA is the macroscopic dissociation 
equilibrium constant [equivalent to the effec-
tive concentration causing 50% of maximal 
response (EC50)], and αA is the maximal 
effect level of the ligand in the tissue or sys-
tem under study. This function is usually a 
good fit for dioxin-like agents (Toyoshiba 
et al. 2004). Four-parameter Hill function 
fits of the individual concentration–response 
curves indicated that this was a reasonable 
assumption for our data (Figure 1). Some 
ligands showed a decline in reporter activity 
at the highest doses, a pattern also seen by 
Peters et al. (2006) and Nagy et al. (2002). 
This effect is not explained by frank toxicity 
or by the slight systematic variation in fluoro-
metric readings across each plate. Because the 
decline may indicate a different mechanism of 
action, and as these points were inappropriate 
for fitting with a monotonic Hill function, we 
omitted them from Figure 1 and the analyses.
Substituting the inverse Hill function 
fi
–1(E) = E Ki/(αi – E) into Equation 1, we 
obtain the GCA model for combinations of 
A and B: 
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Isoboles of Equation 2 are found by solv-
ing for [B] and will always be straight lines. 
Under GCA, isoboles of agents with differ-
ent maximal effects need not be parallel, but 
slopes can vary with effect level E:
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Table 1. Isobole shapes for special cases of GCA of two agents described by Hill functions (Hill  
parameter = 1).
Case Slopes of isobolesa
CA Negative, not necessarily equal
TEFs Negative and equal
Competitive antagonism Positive
Partial agonist Negative below maximal effect level of partial agonist, positive above
aUnder GCA, all isoboles are linear.
Figure 1. H1G1 concentration–response curves for experimental agents. Response is given in naïve- 
corrected relative fluorescence units. Lines are fits to Hill functions with a Hill parameter of 1.
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As shown by Equation 3, isoboles of this 
GCA combination are negatively sloped at 
low effect levels, flatten as the combination 
effect increases, and are positively sloped (like 
isoboles of a competitive antagonist) at effects 
above the maximal effect of the partial agonist 
αA. Under GCA, the relative potency (REP) 
of A compared with B at effect level E equals 
the negative of the slope for E ≤ αA and is larg-
est in the limit of small effect: (αA/αB)(KB/KA).
The TEF method assumes that agent A 
has a concentration–response curve parallel 
to the reference agent B with the same maxi-
mum (αA = αB). The joint effect is given by
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where γ is the TEF value, assumed constant 
for all effect levels: γ = KB / KA. For γ < 1, 
A acts as a diluted form of B. The TEF model 
is thus a special case of CA where all isoboles 
are parallel with slope –γ.
Model fitting and significance test-
ing. Individual (marginal) concentration– 
response functions were fit to a Hill function 
with Hill parameter n=1, using the optim() 
minimization function (specifying BFGS, 
a quasi-Newton method) in R (2.4.1; 
The R Project for Statistical Computing, 
http://www.r-project.org). The fluorescence 
value in the doubly unexposed well ([A]=0, 
[B]=0) was subtracted from the averaged com-
bination matrices before fitting. The expected 
response surfaces for combinations were then 
calculated by substituting marginal fit param-
eters into Equations 2 and 4. For Equation 4, 
we used the experimentally determined REP 
value (i.e., the ratio of the EC50 values) for γ. 
Experimental and model response surfaces were 
plotted with the R wireframe() function and 
are linear interpolations between data points (at 
intersections of line segments). Isobolograms 
were generated with the R contour() function 
and are interpolated between data points.
To test the fit of the modeled response 
surface to the experimental data, we used 
the non  parametric Mann–Whitney test 
(Wilcoxon rank sum), performed using wil-
cox.test() in R. This statistic tests the hypoth-
esis that the experimental data and modeled 
data come from the same distribution; a sig-
nificant result (p < 0.05) indicates that the dis-
tributions differ. An alternative non  parametric 
test, Kolmogorov–Smirnov, produced similar 
results (data not shown). For visual inspec-
tion, the empirical cumulative distribution 
functions (ECDFs) of the experimental and 
model surfaces were plotted using plot(ecdf()) 
in R [see Supplemental Material, Figure 1 
(doi:10.1289/ehp.0901312)].
The R code used in the analysis and plot-
ting of the mixture data, along with a sample 
data set, is available on the Boston University 
Superfund Research Program web site (http://
www.busrp.org/research.html).
Results
Characterization of single chemical dose– 
response curves. Treatment of H1G1.1c3 cells 
with TCDD, TCDF, PCB126, PCB105, or 
galangin each resulted in activation of the 
AhR, as indicated by the production of EGFP 
controlled by AhR transactivation. The data 
were well described by the assumed Hill func-
tions (Figure 1). Table 2 shows the estimated 
maximal effect, EC50, and REP (the ratio of 
the EC50s) of each compound. As expected, 
TCDD, TCDF, and PCB126 were similarly 
efficacious at activating the AhR (Figure 1). 
The REP of PCB126 compared with TCDD, 
approximately 0.07, is near the 2006 World 
Health Organization (WHO) TEF value of 
0.1 and is well within the order of magnitude 
accuracy expected for TEFs (Van den Berg 
et al. 2006).
The maximal effect of PCB105 was 61% 
of that elicited by TCDD, consistent with its 
characterization as a partial agonist. However, 
Peters et al. (2006) reported a maximal effect 
of approximately 11% of TCDD in this cell 
line after purification of commercial PCB105 
with activated charcoal. The high potency 
of PCB126 compared with PCB105 (Peters 
et al. 2006) suggests that much of the activity 
of our sample is from the impurities rather 
than the target compound. Under GCA, the 
contaminated sample may be treated as a 
single agent, with potency and efficacy inter-
mediate between that of pure PCB105 and 
pure PCB126. Support for this view is pro-
vided by the fact that our REP for PCB105, 
5.4 × 10–6, is larger than the 1 × 10–6 reported 
Table 2. Maximal effect and potency for individual compounds.
AhR ligand Reference compound Maximal effect (%) EC50 (M) REPa
TCDF — 100 2.9 × 10–11
PCB126 TCDF 99 4.1 × 10–10 7.1 × 10–2
TCDD — 100 7.6 × 10–12
PCB105 TCDD 61 1.4 × 10–6 5.4 × 10–6
TCDD — 100 9.9 × 10–12
Galangin TCDD 30 4.1 × 10–6 2.4 × 10–6
TCDD — 100 9.1 × 10–12
DIM TCDD 8b 6.6 × 10–6 1.4 × 10–6
Response characteristics for the tested ligand and the reference compound in each combination were determined by 
fitting dose–response data (see Figure 1) using a four-parameter Hill function. 
aExperimental potency relative to reference compound (calculated as EC50 of reference divided by EC50 of compound) 
used for TEF models. bBecause initial curve fits extrapolated to an unreasonably high maximal response, the maximal 
response was set to the average value at the highest non  toxic dose and the EC50 value alone was fit.
Figure 2. Response surfaces for TCDF plus PCB126 combinations shown for (A) experimental data, (B) TEF model prediction, and (C) GCA model prediction. TEF 
and GCA model surfaces were constructed from marginal concentration–response curves. The x- (TCDF) and y‑ (PCB126) axes are logarithmic, with zero dose 
plotted at 1/10 of the lowest dose; the z‑ (response, E) axis is linear. Concentrations were 10–13 to 10–8 M TCDF and 10–10 to 10–8 M PCB126.
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by Peters et al. (2006) for purified PCB105. 
Both are less than the WHO TEF value of 
3 × 10–5 for mono-ortho PCBs (Van den Berg 
et al. 2006).
The flavonoid galangin is found in two 
species of a gingerlike Asian root (Alpina spp.) 
(Ciolino and Yeh 1999). In the H1G1 assay, 
galangin significantly induced AhR reporter 
activity, although to only 30% of the level 
induced by TCDD (Table 2). Thus, galangin 
was characterized as a partial agonist in these 
experiments.
DIM is a selective AhR modulator found 
in cruciferous vegetables that has been studied 
as a possible chemo  preventive agent for treat-
ing breast cancer (Hestermann and Brown 
2003). DIM had little AhR-related activity 
in the H1G1 assay (approximately 8% of the 
maximal effect of TCDD), making it a nearly 
complete competitive antagonist (Table 2).
TCDF + PCB126. We used mixtures 
of TCDF and PCB126 to assess the effects 
of a combination of two full agonists [see 
Supplemental Material, Table 1 (doi:10.1289/
ehp.0901312) for means ± SEs]. Figure 2A 
shows the experimental response surface (the 
individual dose–response curves of TCDF 
and PCB126 are visible along the x–z and y–z 
faces, respectively). Figure 2B and C show 
expected results using the TEF and GCA 
approaches, respectively. Both models fit the 
data well (p-values for model rejection are 
0.82 for TEF and 0.86 for GCA). For two 
full agonists, we expect the GCA model to 
reduce to the TEF model.
TCDD plus PCB105. For a combina-
tion of a full agonist and a partial agonist, 
we used TCDD and mono-ortho-substituted 
PCB105 [see Supplemental Material, Table 2, 
(doi:10.1289/ehp.0901312), for means ± SEs]. 
The experimental response surface is shown 
in Figure 3A, along with the TEF (Figure 3B) 
and GCA (Figure 3C) model fits. GCA fit the 
data better than the TEF model, although nei-
ther model was significantly rejected (p-values 
for model rejection are 0.08 for TEF and 0.63 
for GCA). The PCB105 sample used for these 
experiments was contaminated with the more 
potent and efficacious PCB126. Because the 
PCB105 sample has relatively high efficacy, its 
competitive effect on TCDD is only moderate; 
consequently, the TEF model, although imper-
fect, is a reasonable description of the experi-
mental data over a large range of effect.
TCDD plus galangin. Galangin is a partial 
agonist of lower efficacy than PCB105 [see 
Supplemental Material, Table 3, (doi:10.1289/
ehp.0901312), for means ± SEs]. The GCA 
model (Figure 4C) fit the experimental 
response surface (Figure 4A) extremely well 
(p for rejection = 0.79), whereas the TEF 
model was visibly inappropriate (Figure 4B) 
and was strongly rejected (p for rejection = 
4 × 10–5). The difference between the mod-
els is apparent in Supplemental Material, 
Figure 1: The empirical cumulative distribu-
tion function (ECDF) for GCA closely fol-
lows the experimental data, whereas the TEF 
ECDF provides an extremely poor fit. The 
TEF model fails at high doses because it can-
not take into account the reduced effect that 
occurs when the lower-efficacy galangin com-
petes with TCDD for receptors.
Isoboles must be straight lines under GCA, 
but application of this visual test requires 
Figure 3. Response surfaces for TCDD plus PCB105 combinations shown for (A) experimental data, (B) TEF model prediction, and (C) GCA model prediction. TEF 
and GCA model surfaces were constructed from marginal concentration–response curves. The x‑ (TCDD) and y‑ (PCB105) axes are logarithmic, with zero dose 
plotted at 1/10 of lowest dose; z‑ (response, E) axis is linear. Concentrations were 10–13 to 2 × 10–10 M TCDD and 10–7 to 10–5 M PCB105.
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Figure 4. Response surfaces for TCDD plus galangin combinations shown for (A) experimental data, (B) TEF model prediction, and (C) GCA model prediction. TEF 
and GCA model surfaces were constructed from marginal concentration–response curves. The x‑ (TCDD) and y‑ (galangin) axes are logarithmic, with zero dose 
plotted at 1/10 of the lowest dose; z‑ (response; E) axis is linear. Concentrations were 10–13 to 2 × 10–10 M TCDD and 2.5 × 10–6 to 3 × 10–5 M galangin.
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arithmetic x- and y-axes instead of the loga-
rithmic axes commonly used in toxicology. 
We therefore performed additional experi-
ments with a narrower range of linearly spaced 
doses (Figure 5A) [see Supplemental Material, 
Table 4, (doi:10.1289/ehp.0901312), for 
means ± SEs]. The isoboles of this surface 
(Figure 5B) approximately follow the GCA 
model, switching from negative to posi-
tive slopes near TCDD concentrations of 
5 × 10–12 M as predicted by Equation 3. The 
isoboles are not perfectly linear because of 
minor variations in the response surface.
TCDD plus DIM. Figure 6A shows the 
experimental response surface for combina-
tions of the full agonist TCDD and the nearly 
complete competitive antagonist DIM [see 
Supplemental Material, Table 5 (doi:10.1289/
ehp.0901312) for means ± SEs]. As shown in 
Figure 6B, GCA fit the data well (p for rejec-
tion = 0.65). Because of the very low efficacy 
of DIM, we considered a TEF model inappro-
priate for these data.
Discussion
Humans and wildlife are rarely exposed to 
individual PCBs, dioxins, or other AhR ago-
nists. Most environmental exposures to these 
chemicals consist of at least dozens of indi-
vidual agents with varying potencies and dif-
fering maximal effects. Risk assessment must 
describe the joint effects of such a mixture, 
whereas toxicologists need to assess the types 
of inter  action occurring among chemicals in 
the mixture. The TEF approach estimates an 
equivalent combination dose using the con-
centrations and relative potencies of individual 
congeners, but it ignores differences in maxi-
mal effects, thereby failing to account for the 
competition of partial agonists for receptor 
sites. The presence of weak agonists is a known 
limitation of the TEF approach (Safe 1997); 
however, although mechanistic models analo-
gous to that used here have occasionally been 
derived for other systems (e.g., effects of sol-
vents on upper respiratory irritation in rats) 
under the name competitive agonism (Cassee 
et al. 1996), models that can account for the 
competitive effect of a partial agonist have 
only rarely been applied (Hestermann et al. 
2000). Here, we show that GCA accurately 
predicts this effect.
We implemented the generic GCA 
model (Equation 1) for the case of two agents 
described by Hill functions with Hill param-
eter of 1 (Equation 2) and calculated the TEF 
model for the same agents (Equation 4). We 
tested the ability of each model to predict the 
effect on AhR activation of combinations of 
a full agonist with a full agonist, a full agonist 
with a partial agonist, and a full agonist with a 
nearly complete competitive antagonist. In each 
case, the GCA-modeled response surface fit 
the experimental data well. For lower-efficacy 
compounds, GCA fit the data sub  stantially 
better than the TEF model. The TEF model 
was close to rejection for PCB105 and strongly 
rejected for galangin.
The isobologram, which is at the heart of 
the CA definition (Berenbaum 1989), was less 
useful in testing non  interactivity. Because the 
isobologram is plotted on the arithmetic scale 
of doses, it requires different dose selection 
within a much narrower range to evenly cover 
the appropriate dose–dose space. Calculation of 
isoboles requires interpolation of the response-
surface contours from a relatively small num-
ber of doses (Figure 5); unfortunately, small 
variations in effect level cause variations in 
the response surface, which can distort isobole 
shapes. Instead, the response-surface plots, 
model fits, and non  parametric statistical tests 
appear to provide more robust visualization 
and analysis of the combination data.
Utility of the GCA method. Use of the 
GCA method is not limited to the type of 
analysis described here. For instance, in some 
cases, GCA allows simple calculation of an 
equivalent dose of a reference agent. Suppose 
two agents A and B, described by Hill func-
tions as above, occur in a mixture at constant 
dose ratio c = [A]/[B]. The mixture can be 
described as a single agent with summed dose 
[X]=[A] + [B] and parameters
  K
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For example, a combination of equal doses of 
a full agonist B and a partial agonist A, where 
αA = 0.1, KA = KB , and c=1, yields a mixture 
(X) with a maximal effect αX = 11/20 αB.
Our specific implementation was for com-
binations of two agents described by Hill func-
tions with Hill coefficient of 1, but the GCA 
model may, in principle, be used for any group 
of agents whose dose–response curves can be 
Figure 5. Response surface with arithmetic axes (A) and isobolographic analysis (B) of TCDD plus galangin 
combinations. For the isobologram of this surface (B), contours are interpolated between data points 
(circles). Arithmetic x‑ (TCDD) and y‑ (galangin) axes are identical in these plots. The GCA model predicts 
a vertical isobole near 5 × 10–12 M TCDD. Concentrations were 5 × 10–13 to 2 × 10–11 M TCDD and 10–6 to 
10–5 M galangin.
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Figure 6. Response surfaces for TCDD plus DIM combinations shown for (A) experimental data and 
(B) GCA model prediction. The GCA model surface was constructed from marginal concentration–
response curves. The x‑ (TCDD) and y‑ (DIM) axes are logarithmic, with zero dose plotted at 1/10 of low-
est dose; z‑ (response, E) axis is linear. No TEF model was fit to these data. Concentrations were 10–13 to 
10–10 M TCDD and 10–6 to 2 × 10–5 M DIM.
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represented with appropriately invertible func-
tions. Although we discussed only binary com-
binations, the GCA method can handle more 
complex mixtures. For combinations of agents 
Ci, at effect level E, Equation 1 becomes
  ,
fE
C
1
c
i
i
1
i
= - ^h
6@ /   [6]
from which follow equations analogous to 
Equations 2 and 5 for treatment of multiple 
agents. In these ways, GCA lends itself to cal-
culations of total effects of combination doses 
and to analysis of combinations containing 
more than two compounds. Thus, using 
straightforward modifications, the contexts in 
which GCA can be used are broadened.
Implications for the TEF approach. The 
TEF approach assumes a constant REP at 
every effect level. By contrast, the GCA model 
predicts relative potencies that may vary with 
effect level. Because the TEF method does not 
account for the competitive effect of the partial 
agonist on the full agonist, it generally over-
estimates the joint effect compared with GCA. 
This difference is most pronounced at high 
effect levels and at higher relative concentra-
tions of the partial agonist. For the concen-
tration–response functions used here, a TEF 
model will always over  predict joint effects. For 
example, given a partial agonist A with a maxi-
mal effect 10% of full agonist B (αA = 0.1 αB), 
the TEF model over  estimates joint effects by a 
factor of about 1.8 for combination doses given 
in the ratio [A]/[B] = KA/KB (i.e., each agent is 
dosed at a constant multiple of its EC50). For 
larger relative concentrations of partial ago-
nist A, the TEF model over  estimates the effect 
predicted by the GCA model by up to a factor 
of αB/αA; for larger relative concentrations of 
B, the partial agonist is less important and the 
TEF model approaches the GCA model.
For more complex mixtures, Equation 5 
is easily extended, and the effective maximum 
becomes an average of the maxima of mix-
ture components, weighted by the dose of each 
agent relative to its own EC50. As more partial 
agonists—or a higher dose of one partial ago-
nist—are added to the mixture, the maximum 
effect of the mixture is reduced toward the effi-
cacy of the least effective agent. For example, a 
mixture of one full agonist with ten 10% par-
tial agonists (with each agent dosed at its own 
EC50) will have a maximal efficacy of 2/11 
(18%). (The same result is obtained with one 
full agonist, dosed at its EC50, with one partial 
agonist, dosed at 10 times its EC50.) Although 
this particular result is within the order of 
magnitude accuracy attributed to the TEF 
approach (Van den Berg et al. 2006), the dis-
crepancy between results of the GCA and TEF 
models would be even greater for mixtures that 
include numerous partial agonists or partial 
agonists in relatively high concentrations.
It has long been recognized that the TEF 
assumption of parallel dose–response curves 
may not be appropriate for some PCBs. 
Both individual PCB congeners and Aroclor 
mixtures have been shown to antagonize the 
AhR activity of full agonists such as TCDD 
(Aarts et al. 1995; Safe 1998); consequently, 
“the TEF approach overestimates the toxic-
ity of these mixtures” (Harper et al. 1995). 
GCA would be expected to predict the lower 
effect levels of mixtures of low-efficacy PCBs 
and full AhR agonists. Further work will be 
required to test whether a GCA model, when 
applied to the specific experimental combina-
tions, can explain these nonadditive inter-
actions (Harper et al. 1995). Indeed, the use 
of the terms “nonadditive” or “antagonistic” 
demon  strates the difficulty of clear termi-
nology in this field. Because the GCA null 
model describes the decreased joint effect of 
combinations that include partial agonists or 
competitive antagonists, those combinations 
may be thought of as additive in the sense 
of following the null model. In such cases, 
use of the term “non  interactive” in place of 
“additive” may be clearer.
Finally, commercially available “pure” 
PCB congeners are often contaminated with 
other congeners. Specific values obtained from 
laboratory assays using contaminated samples 
are likely to over  estimate both the potency and 
the maximal effect of partial agonist ligands, in 
turn over  estimating the REP and TEF values. 
The competitive–antagonistic effect of PCBs 
that are partial agonists is likely to be even 
more important with pure samples than with 
estimates derived from contaminated samples.
In sum, we found that the GCA model fit 
experimental data on mixtures of a diverse set 
of AhR ligands better than the TEF model. 
An important limitation of our results is 
that we used an in vitro reporter assay that 
does not take into account in vivo metabo-
lism and pharmaco  kinetics, particularly for 
less-  persistent AhR ligands, and the potential 
dependence of maximal effect levels on the 
choice of end point. Nevertheless, some of the 
PCBs currently classified as dioxin-like com-
pounds and provided with TEFs appear to 
exhibit some degree of partial agonism (Aarts 
et al. 1995; Safe 1998). Our results suggest 
that application of TEFs to mixtures contain-
ing these compounds will tend to over  estimate 
effects, with the discrepancy increasing with 
dose or relative amounts of partial agonists 
and antagonists. The implications depend on 
the use of the analysis. For judging toxicologic 
inter  action (i.e., additivity vs. non  additivity), 
we believe GCA will provide greater insight 
than the TEF model. For this purpose, it is 
essential to measure both REP and efficacy. 
For risk assessment of environ  mental expo-
sures, use of TEFs may provide an adequate 
estimate at low doses, given the goal of an 
order of magnitude accuracy of the current 
system and the lack of an established database 
of efficacies similar to the existing database of 
potencies. For the dose–response curves we 
evaluated, the TEF system would provide a 
conservative (i.e., high) estimate of the tox-
icity of the mixture, a commonly accepted 
practice in risk assessment. In the long run, 
we believe that risk assessment of AhR ligands 
and other types of mixtures would benefit 
from increased attention to partial agonism. 
The GCA model provides one approach.
Conclusions
GCA predicted joint effects of full ago-
nist, partial agonist, and near-competitive 
antagonist combinations of AhR ligands. 
This approach has the potential to improve 
analysis and risk assessment of mixtures cur-
rently modeled with the TEF method. The 
GCA approach is not a mechanistic model 
but a broadly applicable definition of non-
interaction. Consequently, GCA may be 
useful for analyzing other systems with dif-
ferent dose–response curves, possibly includ-
ing estrogenic agents or phthalates. The 
GCA approach may be useful in classifying 
inter  actions of mixtures as well as in making 
predictions about their effects when the indi-
vidual dose–response curves are well known.
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